Recursion Pharmaceuticals, Inc. (RXRX) News
Track canonical SquawkNews coverage tagged to RXRX, Recursion Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TEM RXRX - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
TEM RXRX - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
NEWS | Sep 21, 2026, 01:23 PM UTC
M
Recursion resets Tempus data pact and licenses TxFM RNA model in $12M deal
Recursion amended its long-term data collaboration with Tempus, extending the Master Agreement to a six-year term from a Nov. 3, 2023 start, removing its convenience termination right, and resetting Annual License Fees.
EQUITY | Sep 21, 2026, 01:14 PM UTC
H
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Recursion Pharmaceuticals (NASDAQ: RXRX ) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For
LIVE | Sep 17, 2026, 01:22 PM UTC
L
RXRX: AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones
The company has transformed into an end-to-end AI-driven drug discovery leader, achieving significant cost reductions and clinical progress with first-in-class assets like REC-4881 and REC-1245. Strategic partnerships wi
NEWS | Sep 15, 2026, 02:21 PM UTC
L
RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones
The conference highlighted a strategic transformation to an AI-driven, end-to-end drug discovery engine, with significant cost reductions and repeatable productivity. Key clinical assets like REC-4881 and REC-1245 are ad
NEWS | Sep 15, 2026, 01:36 PM UTC
L
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub-areas which have all rallied behind the MRNA/MRK news today
EQUITY | Aug 19, 2026, 07:34 PM UTC
H
Cramer likes Vistra, Constellation Energy, Fastly after earnings
Jim Cramer said he likes Vistra and Constellation Energy on CNBC, called Fastly “back from the abyss,” and said Recursion, NextEra and Huntington Ingalls on the show.
EARNINGS | Aug 13, 2026, 12:00 PM UTC
L
RXRX - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program - Click
RXRX - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
EARNINGS | Aug 05, 2026, 10:30 AM UTC
L
RXRX Grants Inducement Awards
RXRX grants inducement awards
EQUITY | Jul 31, 2026, 08:30 PM UTC
L
RXRX - Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
RXRX - Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
EARNINGS | Jul 29, 2026, 12:30 PM UTC
L
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
2026-07-03 11:34:15 ET As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driv
EQUITY | Jul 03, 2026, 03:34 PM UTC
H
Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI
While corporate America is becoming more selective about using artificial intelligence as a rationale for acquisitions, Anthropic is making its biggest bet yet that AI will reshape scientific research. The AI startup on
MNA | Jul 01, 2026, 11:50 AM UTC